선바이오(주) / SunBio, Inc.
SunBio, Inc.'s KOBDi Score is 151.39 as of Sep 2026, up 16.69 points since Apr 2025; it rose in 6 and fell in 3 of the 12 monthly updates. As of Sep 2026 it is ahead of about 93% of companies in its industry, against 93% in Aug 2026 and 79% in Apr 2025. Its strongest position was 93% (Sep 2026) and its weakest 18% (Dec 2025).
A year earlier, in Aug 2025, its score was 135.58 and it was ahead of about 80% of companies in its industry.
| Sep 2026 | 151.39 | ahead of 93% |
| Aug 2026 | 151.17 | ahead of 93% |
| Jul 2026 | 66.44 | ahead of 21% |
| Jun 2026 | 65.96 | ahead of 21% |
| May 2026 | 66.38 | ahead of 20% |
| Apr 2026 | 66.38 | ahead of 20% |
| Mar 2026 | 66.38 | ahead of 20% |
| Feb 2026 | 66.29 | ahead of 20% |
| Dec 2025 | 65.65 | ahead of 18% |
| Aug 2025 | 135.58 | ahead of 80% |
| Jul 2025 | 134.54 | ahead of 79% |
| May 2025 | 134.70 | ahead of 80% |
| Apr 2025 | 134.70 | ahead of 79% |
Where is SunBio, Inc. located?
SunBio, Inc. is registered at Sanbon-ro, Gunpo-si, Gyeonggi-do, South Korea (postal code 21639).
What industry is SunBio, Inc. in?
SunBio, Inc. belongs to Manufacturing › Pharmaceuticals & Biologics › Finished pharmaceutical manufacturing.
How many employees does SunBio, Inc. have?
SunBio, Inc. has 20–29 employees.
Is SunBio, Inc. a public company?
Yes. SunBio, Inc. is listed on KOSDAQ under the ticker Not available since 2022.
What is SunBio, Inc.'s KOBDi Score?
151.39 as of September 2026, ahead of about 93% of companies in its industry.
Who are SunBio, Inc.'s competitors?
Similar companies include OSANG HEALTHCARE, HANLIM PHARM and Hana Pharm.


